Prime Medicine, Inc. Common Stock (PRME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has a cash flow conversion efficiency ratio of -0.217x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.04 Million) by net assets ($161.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prime Medicine, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Prime Medicine, Inc. Common Stock for a breakdown of total debt and financial obligations.
Prime Medicine, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D&O Home Collection Co Ltd
SHE:002798
|
0.035x |
|
Guizhou Taiyong Changzheng Technology Co Ltd Class A
SHE:002927
|
-0.004x |
|
Uxin Ltd
NASDAQ:UXIN
|
0.177x |
|
Regal Partners Ltd
AU:RPL
|
0.048x |
|
Haier Smart Home Co Ltd
F:690D
|
0.043x |
|
Oeneo SA
PA:SBT
|
0.044x |
|
Tianjin LVYIN Landscape and Ecology Construction Co Ltd
SHE:002887
|
0.001x |
|
Forward Air Corporation
NASDAQ:FWRD
|
-0.141x |
Annual Cash Flow Conversion Efficiency for Prime Medicine, Inc. Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Prime Medicine, Inc. Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Prime Medicine, Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $153.15 Million | $-122.86 Million | -0.802x | +35.46% |
| 2023-12-31 | $133.07 Million | $-165.41 Million | -1.243x | -198.22% |
| 2022-12-31 | $316.27 Million | $-131.83 Million | -0.417x | -192.98% |
| 2021-12-31 | $239.56 Million | $-34.08 Million | -0.142x | +14.10% |
| 2020-12-31 | $33.47 Million | $-5.54 Million | -0.166x | +82.76% |
| 2019-12-31 | $1.39 Million | $-1.33 Million | -0.960x | -- |
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more